Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
insulin
December 2021
November 2021
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
